|
1
|
Argani P, Hawkins A, Griffin CA, Goldstein
JD, Haas M, Beckwith JB, Mankinen CB and Perlman EJ: A distinctive
pediatric renal neoplasm characterized by epithelioid morphology,
basement membrane production, focal HMB45 immunoreactivity, and
t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol.
158:2089–2096. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Srigley JR, Delahunt B, Eble JN, Egevad L,
Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, et
al: ISUP Renal Tumor Panel: The International Society of Urological
Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J
Surg Pathol. 37:1469–1489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhan HQ, Wang CF, Zhu XZ and Xu XL: Renal
cell carcinoma with t(6;11) translocation: A patient case with a
novel Alpha-TFEB fusion point. J Clin Oncol. 28:e709–e713. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuiper RP, Schepens M, Thijssen J, van
Asseldonk M, van den Berg E, Bridge J, Schuuring E, Schoenmakers EF
and van Kessel AG: Upregulation of the transcription factor TFEB in
t(6;11)(p21;;q13)-positive renal cell carcinomas due to promoter
substitution. Hum Mol Genet. 12:1661–1669. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davis IJ, Hsi BL, Arroyo JD, Vargas SO,
Yeh YA, Motyckova G, Valencia P, Perez-Atayde AR, Argani P, Ladanyi
M, et al: Cloning of an Alpha-TFEB fusion in renal tumors harboring
the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci
USA. 100:6051–6056. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Argani P, Laé M, Hutchinson B, Reuter VE,
Collins MH, Perentesis J, Tomaszewski JE, Brooks JS, Acs G, Bridge
JA, et al: Renal carcinomas with the t(6;11)(p21;;q12):
Clinicopathologic features and demonstration of the specific
alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA
PCR. Am J Surg Pathol. 29:230–240. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Argani P, Laé M, Ballard ET, Amin M,
Manivel C, Hutchinson B, Reuter VE and Ladanyi M: Translocation
carcinomas of the kidney after chemotherapy in childhood. J Clin
Oncol. 24:1529–1534. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pecciarini L, Cangi MG, Lo Cunsolo C,
Macri' E, Dal Cin E, Martignoni G and Doglioni C: Characterization
of t(6;11) (p21;q12) in a renal-cell carcinoma of an adult patient.
Genes Chromosomes Cancer. 46:419–426. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Camparo P, Vasiliu V, Molinie V, Couturier
J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R,
et al: Renal translocation carcinomas: Clinicopathologic,
immunohistochemical, and gene expression profiling analysis of 31
cases with a review of the literature. Am J Surg Pathol.
32:656–670. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Geller JI, Argani P, Adeniran A, Hampton
E, De Marzo A, Hicks J and Collins MH: Translocation renal cell
carcinoma: Lack of negative impact due to lymph node spread.
Cancer. 112:1607–1616. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hora M, Hes O, Urge T, Eret V, Klecka J
and Michal M: A distinctive translocation carcinoma of the kidney
['rosette-like forming,' t(6;11), HMB45-positive renal tumor]. Int
Urol Nephrol. 41:553–557. 2009. View Article : Google Scholar
|
|
12
|
Suárez-Vilela D, Izquierdo-García F,
Méndez-Álvarez JR, Miguélez-García E and Domínguez-Iglesias F:
Renal translocation carcinoma with expression of TFEB: Presentation
of a case with distinctive histological and immunohistochemical
features. Int J Surg Pathol. 19:506–509. 2011. View Article : Google Scholar
|
|
13
|
Ishihara A, Yamashita Y, Takamori H and
Kuroda N: Renal carcinoma with (6;11)(p21;q12) translocation:
Report of an adult case. Pathol Int. 61:539–545. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Petersson F, Vaněček T, Michal M,
Martignoni G, Brunelli M, Halbhuber Z, Spagnolo D, Kuroda N, Yang
X, Cabrero IA, et al: A distinctive translocation carcinoma of the
kidney; 'rosette forming,' t(6;11), HMB45-positive renal tumor: A
histomorphologic, immunohistochemical, ultrastructural, and
molecular genetic study of 4 cases. Hum Pathol. 43:726–736. 2012.
View Article : Google Scholar
|
|
15
|
Inamura K, Fujiwara M, Togashi Y, Nomura
K, Mukai H, Fujii Y, Yamamoto S, Yonese J, Fukui I and Ishikawa Y:
Diverse fusion patterns and heterogeneous clinicopathologic
features of renal cell carcinoma with t(6;11) translocation. Am J
Surg Pathol. 36:35–42. 2012. View Article : Google Scholar
|
|
16
|
Argani P, Yonescu R, Morsberger L, Morris
K, Netto GJ, Smith N, Gonzalez N, Illei PB, Ladanyi M and Griffin
CA: Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma
in archival paraffin-embedded material using a break-apart TFEB
FISH assay expands its clinicopathologic spectrum. Am J Surg
Pathol. 36:1516–1526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rao Q, Liu B, Cheng L, Zhu Y, Shi QL, Wu
B, Jiang SJ, Wang Y, Wang X, Yu B, et al: Renal cell carcinomas
with t(6;11)(p21;q12): A clinicopathologic study emphasizing
unusual morphology, novel alpha-TFEB gene fusion point,
immunobiomarkers, and ultrastructural features, as well as
detection of the gene fusion by fluorescence in situ hybridization.
Am J Surg Pathol. 36:1327–1338. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhong M, De Angelo P, Osborne L,
Paniz-Mondolfi AE, Geller M, Yang Y, Linehan WM, Merino MJ,
Cordon-Cardo C and Cai D: Translocation renal cell carcinomas in
adults: A single-institution experience. Am J Surg Pathol.
36:654–662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bambury RM, Battley JE, McCarthy A, Brady
C, O'Reilly S, Kelly PJ, O'Brien F, Sweeney P, Fleming S, Mayer NJ,
et al: Translocation renal cell carcinomas: An evolving entity and
a member of the microphthalmia transcription factor-associated
family of tumors. Clin Genitourin Cancer. 11:357–361. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rao Q, Zhang XM, Tu P, Xia QY, Shen Q,
Zhou XJ and Shi QL: Renal cell carcinomas with t(6;11)(p21;;q12)
presenting with tubulocystic renal cell carcinoma-like features.
Int J Clin Exp Pathol. 6:1452–1457. 2013.
|
|
21
|
Chaste D, Vian E, Verhoest G and Blanchet
P: Translocation renal cell carcinoma t(6;11)(p21;;q12) and sickle
cell anemia: First report and review of the literature. Korean J
Urol. 55:145–147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Smith NE, Illei PB, Allaf M, Gonzalez N,
Morris K, Hicks J, Demarzo A, Reuter VE, Amin MB, Epstein JI, et
al: t(6;11) renal cell carcinoma (RCC): Expanded
immunohistochemical profile emphasizing novel RCC markers and
report of 10 new genetically confirmed cases. Am J Surg Pathol.
38:604–614. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hora M, Urge T, Trávníček I, Ferda J,
Chudáček Z, Vaněček T, Michal M, Petersson F, Kuroda N and Hes O:
MiT translocation renal cell carcinomas: Two subgroups of tumours
with translocations involving 6p21 [t (6; 11)] and Xp11.2 [t (X;1
or X or 17)]. Springerplus. 3:2452014. View Article : Google Scholar
|
|
24
|
Peckova K, Vanecek T, Martinek P, Spagnolo
D, Kuroda N, Brunelli M, Vranic S, Djuricic S, Rotterova P, Daum O,
et al: Aggressive and nonaggressive translocation t(6;11) renal
cell carcinoma: Comparative study of 6 cases and review of the
literature. Ann Diagn Pathol. 18:351–357. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao Y, Yao J, Chen N, Zeng H and Zhang W:
Renal cell carcinomas with t(6;11) (p21;q12): Presentation of two
cases with computed tomography findings. Jpn J Radiol. 33:380–383.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arneja SK and Gujar N: Renal cell
carcinoma with t(6:11) (p21;q12). A case report highlighting
distinctive immunohistologic features of this rare tumor. Int J
Surg Case Rep. 7C:16–19. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lilleby W, Vlatkovic L, Meza-Zepeda LA,
Revheim ME and Hovig E: Translocational renal cell carcinoma
(t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification
and an integrated precision approach: A case report. J Med Case
Reports. 9:2812015. View Article : Google Scholar
|
|
28
|
Xia Q, Shi S, Shen Q, Wei X, Wang X, Ma H,
Lu Z, Zhou X and Rao Q: Renal cell carcinoma with
t(6;11)(p21;2;q13)/MALAT1-TFEB fusion: A clinical and pathological
analysis. Zhonghua Bing Li Xue Za Zhi. 44:895–899. 2015.In
Chinese.
|
|
29
|
Williamson SR, Eble JN and Palanisamy N:
Sclerosing TFEB-rearrangement renal cell carcinoma: A recurring
histologic pattern. Hum Pathol. 62:175–179. 2017. View Article : Google Scholar
|
|
30
|
Guru SC, Agarwal SK, Manickam P, Olufemi
SE, Crabtree JS, Weisemann JM, Kester MB, Kim YS, Wang Y,
Emmert-Buck MR, et al: A transcript map for the 2.8-Mb region
containing the multiple endocrine neoplasia type 1 locus. Genome
Res. 7:725–735. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brodaczewska KK, Szczylik C, Fiedorowicz
M, Porta C and Czarnecka AM: Choosing the right cell line for renal
cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee M, Dworkin AM, Gildea D and Trivedi
NS; NISC Comparative Sequencing Program, Moorhead GB and Crawford
NP: RRP1B is a metastasis modifier that regulates the expression of
alternative mRNA isoforms through interactions with SRSF1.
Oncogene. 33:1818–1827. 2014. View Article : Google Scholar :
|
|
33
|
Magers MJ, Udager AM and Mehra R: MiT
family translocation-associated renal cell carcinoma: A
contemporary update with emphasis on morphologic, immunophenotypic,
and molecular mimics. Arch Pathol Lab Med. 139:1224–1233. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhan HQ, Chen H, Wang CF and Zhu XZ: A
case of PSF-TFE3 gene fusion in Xp11.2 renal cell carcinoma with
melanotic features. Hum Pathol. 46:476–481. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kauffman EC, Ricketts CJ, Rais-Bahrami S,
Yang Y, Merino MJ, Bottaro DP, Srinivasan R and Linehan WM:
Molecular genetics and cellular features of TFE3 and TFEB fusion
kidney cancers. Nat Rev Urol. 11:465–475. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Argani P: MiT family translocation renal
cell carcinoma. Semin Diagn Pathol. 32:103–113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Davis IJ, Kim JJ, Ozsolak F, Widlund HR,
Rozenblatt-Rosen O, Granter SR, Du J, Fletcher JA, Denny CT,
Lessnick SL, et al: Oncogenic MITF dysregulation in clear cell
sarcoma: Defining the MiT family of human cancers. Cancer Cell.
9:473–484. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Giatromanolaki A, Kalamida D, Sivridis E,
Karagounis IV, Gatter KC, Harris AL and Koukourakis MI: Increased
expression of transcription factor EB (TFEB) is associated with
autophagy, migratory phenotype and poor prognosis in non-small cell
lung cancer. Lung Cancer. 90:98–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Klein K, Werner K, Teske C, Schenk M,
Giese T, Weitz J and Welsch T: Role of TFEB-driven autophagy
regulation in pancreatic cancer treatment. Int J Oncol. 49:164–172.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pinilla-Ibarz J, Sweet K, Emole J and
Fradley M: Long-term BCR-ABL1 tyrosine kinase inhibitor therapy in
chronic myeloid leukemia. Anticancer Res. 35:6355–6364.
2015.PubMed/NCBI
|
|
41
|
Ou SH: Crizotinib: A novel and
first-in-class multitargeted tyrosine kinase inhibitor for the
treatment of anaplastic lymphoma kinase rearranged non-small cell
lung cancer and beyond. Drug Des Devel Ther. 5:471–485. 2011.
View Article : Google Scholar : PubMed/NCBI
|
